Cypherpunk Technologies Inc. (LPTX)
NASDAQ
Real-time Data
01:30 PM
Day's Range
1.1952 wk Range
0.2630Overview - LPTX - Cypherpunk Technologies Inc.
Key Statistics
Valuation
Enterprise Value
66.86M
P/E (Trailing)
‪-0.78‬
P/E (Forward)
‪-1.64‬
PEG Ratio
‪0.0095‬
Price / Book
‪2.24‬
EV / EBITDA
‪-1.06‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-77.23%‬
Return on Equity
‪-183.72%‬
Ownership
Shares Outstanding
41.43M
Float
30.40M
Short % of Shares Outstanding
‪5.76%‬
Held by Insiders
‪11.91%‬
Held by Institutions
‪28.71%‬
Price stats
Beta
‪0.08‬
50-Day Avg
‪0.8336‬
200-Day Avg
‪0.4762‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Market Cap - LPTX - Cypherpunk Technologies Inc.
Peers - LPTX - Cypherpunk Technologies Inc.
Peer Comparison
Compared with companies in Asset Management listed on NASDAQ.
- LPTXNASDAQCypherpunk Technologies Inc.60.61MMarket Cap+78.17%52-week change-0.78P/E (Trailing)‪0.00%‬Profit Margin
- CGNASDAQThe Carlyle Group Inc.17.59BMarket Cap-28.96%52-week change51.43P/E (Trailing)‪13.01%‬Profit Margin
- ARCCNASDAQAres Capital Corporation14.30BMarket Cap-10.84%52-week change14.87P/E (Trailing)‪30.90%‬Profit Margin
- FSVNASDAQFirstService Corporation6.34BMarket Cap-38.59%52-week change40.57P/E (Trailing)‪2.88%‬Profit Margin
- FANASDAQFirst Advantage Corporation3.58BMarket Cap+20.24%52-week change139.33P/E (Trailing)‪1.51%‬Profit Margin
- GBDCNASDAQGolub Capital BDC, Inc.3.42BMarket Cap-10.98%52-week change20.00P/E (Trailing)‪21.45%‬Profit Margin
- CSQNASDAQCalamos Strategic Total Return Fund3.32BMarket Cap+11.04%52-week change3.14P/E (Trailing)‪1,347.78%‬Profit Margin
Profile Summary - LPTX - Cypherpunk Technologies Inc.
About
Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches. The company’s lead clinical-stage candidate, DKN-01, is a monoclonal antibody designed to inhibit Dickkopf-related protein 1 and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
